Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1797]

ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana...

ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, USA )

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate...

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from...

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France )

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma

Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias...

ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rummel - University Hospital Giessen, Germany )

ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first...

Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard...

ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-line cabazitaxel ( Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, France )

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with...

Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada...

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )

President's overview of ASCO 2012

Dr Michael Link - Stanford School of Medicine, California, USA

President's overview of ASCO 2012 ( Dr Michael Link - Stanford School of Medicine, California, USA )

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )

New MEK inhibitor, trametinib, improves survival in advanced melanoma

Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France

New MEK inhibitor, trametinib, improves survival in advanced melanoma ( Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France )

First effective treatment for chemotherapy-induced peripheral neuropathy

Dr Ellen Lavoie Smith - University of Michigan, Ann Arbor, USA

First effective treatment for chemotherapy-induced peripheral neuropathy ( Dr Ellen Lavoie Smith - University of Michigan, Ann Arbor, USA )

Afatinib delays progression of advanced lung adenocarcinomas

Dr James Yang - National Taiwan University Hospital, Taipei

Afatinib delays progression of advanced lung adenocarcinomas ( Dr James Yang - National Taiwan University Hospital, Taipei )

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2...

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

EMILIA trial: Trastuzumab emtansine improves progression-free survival in HER2-positive breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA )

Changing the standard treatment for lymphoma with bendamustine

Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany

Changing the standard treatment for lymphoma with bendamustine ( Dr Mathias Rummel - Universitaetsklinik, Giessen, Germany )

More from ecancer